Ibrucent 140 mg contains Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of various B-cell malignancies. It is designed to selectively target and inhibit BTK, a key enzyme in the B-cell receptor signaling pathway that promotes the growth and survival of malignant B-cells. By blocking this pathway, Ibrucent 140 mg helps control disease progression and provides a convenient, targeted therapy for patients with certain blood cancers.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active ingredient: Ibrutinib 140 mg

• Dosage form: Oral capsule

Therapeutic Class

• Bruton's tyrosine kinase (BTK) inhibitor

• Targeted antineoplastic agent

Mechanism of Action

Ibrutinib irreversibly binds to BTK, a critical enzyme in B-cell receptor signaling. Inhibition of BTK disrupts downstream pathways responsible for B-cell proliferation, survival, and migration. This targeted mechanism leads to apoptosis (programmed cell death) of malignant B-cells while sparing most normal cells, allowing for effective disease control with a more favorable safety profile than traditional chemotherapy.

Indications

Ibrucent 140 mg is indicated for the treatment of:

• Chronic Lymphocytic Leukemia (CLL), including cases with 17p deletion

• Mantle Cell Lymphoma (MCL) in patients who have received at least one prior therapy

• Waldenström’s Macroglobulinemia (WM) in adult patients

• Small Lymphocytic Lymphoma (SLL)

• Other B-cell malignancies as determined by a hematologist or oncologist

Dosage and Administration

• The standard dosage of Ibrucent 140 mg is individualized based on the patient’s condition, response to therapy, and tolerability.

• Capsules should be taken orally, preferably at the same time each day, with or without food.

• Swallow capsules whole; do not crush, chew, or open them.

• Dose modifications may be required in patients with hepatic impairment or adverse reactions.

• Regular monitoring of blood counts, liver function, and cardiac health is recommended during therapy.

Benefits and Features

• Oral targeted therapy suitable for outpatient management

• Effective against multiple B-cell malignancies

• Helps reduce tumor burden and improve progression-free survival

• Minimizes off-target toxicity compared with conventional chemotherapy

• Flexible dosing options under specialist supervision

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• May increase the risk of bleeding; patients should be monitored for hemorrhagic events.

• Risk of infections may be elevated; assess and monitor for signs of bacterial, viral, or fungal infections.

• Atrial fibrillation and other cardiac events have been reported; monitor heart rate and rhythm.

• Not recommended during pregnancy or breastfeeding unless specifically advised by a healthcare professional.

• Inform your doctor about all medications, including over-the-counter drugs and supplements, to avoid interactions.

Side Effects

Common side effects include diarrhea, fatigue, bruising, rash, and musculoskeletal pain. Serious adverse reactions may include severe infections, cardiac arrhythmias, bleeding complications, and cytopenias, requiring immediate medical attention.

Storage

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children

Ibrucent 140 mg provides a modern, targeted treatment approach for B-cell malignancies. Under careful medical supervision, it supports effective disease control, delays progression, and improves quality of life for patients with chronic hematologic cancers.